Is neffy available for pediatric patients?

Is neffy cleared for use in children?

Neffy is an epinephrine nasal spray approved for emergency treatment of allergic reactions, including anaphylaxis. The FDA approved the product only for patients 4 years and older who weigh at least 15 kg (33 lb). Children younger than 4 or below that weight still rely on traditional epinephrine auto-injectors.

How does neffy compare with EpiPen in younger children?

No head-to-head pediatric trials have been published. The approval rested on pharmacokinetic and pharmacodynamic data showing that a single 2 mg dose in children 15 kg and heavier produced epinephrine levels comparable to those seen with an intramuscular injection. Dosing in the smallest approved patients still requires the same 2 mg strength; no lower-strength nasal option exists yet.

When might neffy become available for children under 15 kg?

ARS Pharmaceuticals, the maker, is running additional studies in infants and toddlers. Company statements point to possible label expansion in 2025 or later, but no filing date has been confirmed. Any change would still need FDA review and could be delayed by manufacturing or trial outcomes.

Who makes neffy and what does it cost?

ARS Pharmaceuticals markets neffy. The list price is roughly $200–250 per two-pack, similar to branded auto-injectors. Insurance coverage and copay assistance programs vary; some plans treat neffy as a non-preferred specialty product.

Does the patent landscape affect pediatric access?

Neffy’s core patents extend into the early 2030s, according to DrugPatentWatch.com. Those filings cover both the nasal device and the formulation, which may limit near-term generic or lower-cost competitors even after any pediatric expansion.

Are there safety or practical concerns specific to children?

Parents report that the nasal route can be easier to administer during a panic situation, but young children may resist or sneeze the dose out. No new safety signals have emerged in the trials conducted so far, yet real-world data in toddlers remain limited.

[1] https://www.fda.gov/news-events/press-announcements/fda-approves-first-nasal-spray-treatment-emergency-allergic-reactions
[2] https://www.drugpatentwatch.com/drug/neffy